Mushroom Extracts for Dogs: What the Evidence Says About Canine Cognitive Health
By Pawsd Editorial
Last reviewed
Medicinal mushroom extracts — including lion's mane and reishi — are marketed for aging dogs, but controlled canine research is sparse. This review examines the available evidence, explains the evidence gap honestly, and situates mushroom-derived nutraceuticals within the broader literature on canine cognitive aging.
Published
Apr 14, 2026
Updated
Apr 14, 2026
References
7 selected
Canine cognitive aging: the biological context
Canine cognitive dysfunction (CCD) is a neurodegenerative condition observed in aging dogs that shares several pathological features with human Alzheimer's disease. Dogs naturally develop cognitive decline that includes learning and memory deficits, with human-like individual variability in how aging progresses (Ambrosini et al., 2019; PMCID: PMC6591269). Histologically, the aging canine brain can exhibit progressive accumulation of beta-amyloid (Aβ) as diffuse plaques in the prefrontal cortex, hippocampus, and cerebral vasculature (Ambrosini et al., 2019; PMCID: PMC6591269).
A narrative review of CCD reports that the condition may affect a substantial proportion of older dogs, primarily those over 11 years old, though prevalence figures vary across studies (Mihevc and Majdič, 2019; PMCID: PMC6582309). Clinical signs include disorientation, altered activity-rest cycles, and failure to recognize familiar people (Mihevc and Majdič, 2019; PMCID: PMC6582309). Unlike in human Alzheimer's disease, the brains of dogs with CCD rarely contain neurofibrillary tangles (Mihevc and Majdič, 2019; PMCID: PMC6582309), which distinguishes the canine condition mechanistically even as the surface-level presentation resembles human dementia.
Oxidative stress and mitochondrial dysfunction are recognized as key drivers of metabolic decline and cognitive impairment in aging dogs (Cai et al., 2026; DOI: 10.3390/ani16040571). Research on the nutritional needs of aging dogs remains limited, with unclear biomarkers of aging and fragmented research efforts identified as primary barriers (Cai et al., 2026; DOI: 10.3390/ani16040571).
Key takeaway
Canine cognitive dysfunction shares beta-amyloid pathology with human Alzheimer's disease, but the canine population evidence base for nutritional interventions remains underdeveloped. Oxidative stress is a recognized mechanistic driver.
Mushroom extracts: proposed mechanisms and bioactive compounds
Medicinal mushrooms — including Hericium erinaceus (lion's mane), Ganoderma lucidum (reishi), and related species — are proposed to support cognitive and immune function through beta-glucan polysaccharides and other bioactive compounds. A narrative review of plant substances and adaptogens notes that some plant compounds have been proposed to modulate neurotransmitters, reduce oxidative stress, and support cognitive functions (Kępińska-Pacelik et al., 2025; DOI: 10.3390/app15105402). The same review explicitly acknowledges that while research on plant-based compounds in humans is advancing, there is a documented lack of data on their effects in dogs specifically (Kępińska-Pacelik et al., 2025; DOI: 10.3390/app15105402).
In the veterinary nutraceutical literature more broadly, the category of plant extracts and dietary supplements is described as possessing antioxidant, anti-inflammatory, immune-modulating, and cognitive-enhancing properties — characterizations drawn from narrative review rather than canine controlled trials (Nicotra et al., 2025; PMCID: PMC12568156). The same review notes that the veterinary literature also documents drawbacks associated with the use or misuse of such substances (Nicotra et al., 2025; PMCID: PMC12568156).
The proposed biological rationale for mushroom extracts in cognitive aging centers on antioxidant load reduction and neuroprotection. This is consistent with the broader pattern seen in canine antioxidant research, where an enriched antioxidant diet was associated with significantly increased serum levels of brain-derived neurotrophic factor (BDNF) in aged dogs in a single controlled trial (Sechi et al., 2015; PMCID: PMC4590864). BDNF is a protein involved in neuronal survival and plasticity. Whether mushroom-derived compounds specifically replicate or contribute to this pathway in dogs has not been established by controlled research as of the time of this writing.
Key takeaway
The biological rationale for mushroom extracts in canine cognitive aging rests on antioxidant and neuroprotective mechanisms, but most supporting evidence comes from human research or narrative review. Direct canine mechanistic trials are absent from the published literature.
Canine-specific evidence
Controlled canine research on mushroom extracts is sparse. The primary canine-specific study identified in the corpus for this guide is an uncontrolled case series evaluating a mushroom-derived nutraceutical for canine cognitive decline (Unknown, 2025; DOI: 10.46889/jcmr.2025.6327). The study combined owner-reported cognitive assessments with objective wearable activity monitoring (Unknown, 2025; DOI: 10.46889/jcmr.2025.6327). The authors reported positive subjective and objective results and characterized the study as contributing real-world evidence for the use of an all-natural mushroom extract to support cognitive health in aging dogs (Unknown, 2025; DOI: 10.46889/jcmr.2025.6327).
However, the study's conclusions must be interpreted with caution. Biomarker evidence gathered in the study was described as limited and not yet fully validated (Unknown, 2025; DOI: 10.46889/jcmr.2025.6327). The authors themselves called for further investigation with larger cohorts and more rigorous biomarker evaluation (Unknown, 2025; DOI: 10.46889/jcmr.2025.6327). A persistent challenge in veterinary medicine acknowledged in this study is the limited availability of objective data supporting functional supplements such as nutraceuticals, mushrooms, and herbal remedies (Unknown, 2025; DOI: 10.46889/jcmr.2025.6327).
Evidence tier for mushroom extracts in dogs
The available canine evidence for mushroom extracts maps to T3 (one uncontrolled observational case series, unreplicated). This means: the specific study should be named when referenced, and hedging language is required. Framing mushroom extracts as an established cognitive-support intervention for dogs is not supported by the current evidence base.
What owner-reported outcomes measure — and what they do not
The use of owner-reported cognitive assessments as an outcome measure reflects the state of canine cognitive research broadly, where validated clinical instruments exist but biomarker-level confirmation is difficult to achieve in practice. Owner-reported improvement in a non-blinded, uncontrolled design is subject to expectation bias and regression to the mean. These are not criticisms unique to mushroom research — they apply to most veterinary nutraceutical studies.
Key takeaway
The only identified canine-specific study on mushroom-derived nutraceuticals was an uncontrolled case series with limited biomarker support. The authors concluded that further investigation with larger, more rigorous trials is needed. This evidence maps to T3 — emerging and unreplicated.
Mushrooms in the broader nutraceutical landscape
A 2025 systematic review of enriched diets and nutraceuticals for cognitive function in aging dogs and cats found that the existing literature reports inconsistent results, with no consensus on effective interventions (Blanchard et al., 2025; PMCID: PMC12181554). Among the interventions reviewed, omega-3 fatty acids (EPA and DHA) showed the most consistent evidence of potential cognitive benefit in aging dogs, though the authors characterized this as suggesting potential rather than established efficacy (Blanchard et al., 2025; PMCID: PMC12181554). Supplementing with antioxidants alone — such as polyphenols or vitamins E and C — failed to demonstrate significant efficacy on cognitive function in dogs in this systematic review (Blanchard et al., 2025; PMCID: PMC12181554).
Mushroom extracts were not among the compounds with sufficient controlled trials to be independently reviewed in Blanchard et al. (2025). This absence reflects the current evidence gap rather than a negative finding.
A narrative review on canine cognitive dysfunction management notes that cognitive enrichment combined with an antioxidant-rich diet may offer benefits in managing progression and severity of the condition (Mihevc and Majdič, 2019; PMCID: PMC6582309). This framing — diet as one component of a multimodal approach — is consistent with how most veterinary behavior specialists position nutraceuticals: as adjuncts to environmental management and cognitive stimulation, not standalone interventions.
A smaller pilot study examining antioxidant-enriched diets in aged dogs found significant increases in serum BDNF levels after six months, alongside reductions in oxidative stress markers, in an uncontrolled case series (n=36) (Sechi et al., 2015; PMCID: PMC4590864). The authors proposed that an antioxidant-enriched diet may represent a strategy to counteract aging-related cognitive decline (Sechi et al., 2015; PMCID: PMC4590864). Mushroom polysaccharides are proposed to work through overlapping antioxidant pathways, but no controlled study has directly tested this overlap in dogs.
Key takeaway
In the broader canine nutraceutical landscape, omega-3 fatty acids have the strongest (though still preliminary) cognitive-benefit evidence. Mushroom extracts lack sufficient controlled trials to be included in systematic reviews, placing them at an earlier evidence stage than several other nutraceutical categories.
Evidence gaps and limitations
The canine mushroom extract literature has several structural limitations that are important to understand when evaluating product claims:
Absence of randomized controlled trials
No published RCT has evaluated a mushroom-derived compound specifically for canine cognitive outcomes. The gap is acknowledged explicitly in the available case series (Unknown, 2025; DOI: 10.46889/jcmr.2025.6327). Most claims made about lion's mane or reishi in dogs extrapolate from in vitro studies, rodent models, or human research — none of which are reliable proxies for canine bioavailability and cognitive outcomes.
Biomarker validation
Even in the available uncontrolled study, biomarker evidence was described as limited and unvalidated (Unknown, 2025; DOI: 10.46889/jcmr.2025.6327). The broader literature on canine aging notes that unclear biomarkers of aging are a key barrier to nutritional research progress in this species (Cai et al., 2026; DOI: 10.3390/ani16040571). Without validated biomarkers, it is difficult to determine whether a nutraceutical is producing a biologically meaningful effect or merely shifting owner-reported perceptions.
Dosing and formulation heterogeneity
Different mushroom species (lion's mane, reishi, turkey tail, chaga) contain distinct bioactive profiles. Beta-glucan concentrations vary significantly across preparations, and no canine dosing guidelines have been established through controlled research. The practitioner-knowledge register does not contain a sourced entry for mushroom extract dosing in dogs at the time of this writing.
Safety data
The existing canine nutraceutical literature notes that drawbacks associated with the use or misuse of such substances have been reported in the literature (Nicotra et al., 2025; PMCID: PMC12568156). For mushroom extracts specifically, published canine safety data are absent. Dogs with immune-mediated conditions, those on immunosuppressive medications, or those with gastrointestinal conditions warrant veterinary consultation before any immune-modulating supplement is introduced.
Key takeaway
The primary evidence gaps for mushroom extracts in dogs are: no published RCTs, absent or unvalidated biomarker data, no established canine dosing parameters, and limited safety data. The research agenda is early-stage.
How this guide connects to the Pawsd knowledge base
This evidence review covers the current state of canine research on mushroom-derived nutraceuticals — including lion's mane and reishi — with specific attention to the evidence gap between human/rodent research and controlled canine trials. This guide is not a substitute for veterinary advice — aging dogs with cognitive concerns should be evaluated by a veterinarian, who can assess for pain, sensory decline, or other treatable conditions that mimic cognitive dysfunction. The guide is maintained as a living reference and updated as new peer-reviewed evidence is published.
Frequently asked questions
What does the published canine research show about mushroom extracts for cognitive health?
The published canine-specific literature on mushroom extracts consists of a single uncontrolled case series that combined owner-reported cognitive assessments with wearable activity monitoring (Unknown, 2025; DOI: 10.46889/jcmr.2025.6327). The study reported positive subjective and objective results but acknowledged limited biomarker validation and called for larger, more rigorous follow-up studies. This is T3 evidence — a single unreplicated observational study, insufficient to establish efficacy.
How do mushroom extracts compare to other nutraceuticals studied for canine cognitive aging?
A 2025 systematic review of enriched diets and nutraceuticals for pet cognitive function found inconsistent results across the nutraceutical literature as a whole, with omega-3 fatty acids showing the most consistent potential benefit (Blanchard et al., 2025; PMCID: PMC12181554). Mushroom extracts lacked sufficient controlled trials to be independently evaluated in that systematic review. They are at an earlier evidence stage than omega-3 fatty acids, medium-chain triglycerides, or combination antioxidant preparations, each of which has at least one published canine controlled trial.
What is the proposed biological rationale for using medicinal mushrooms in aging dogs?
The biological argument centers on antioxidant and immunomodulatory effects of beta-glucan polysaccharides. Oxidative stress and mitochondrial dysfunction are recognized mechanistic drivers of cognitive impairment in aging dogs (Cai et al., 2026; DOI: 10.3390/ani16040571). Antioxidant-enriched diets have been associated with increased serum BDNF in a small aged-dog trial (Sechi et al., 2015; PMCID: PMC4590864). Whether mushroom-derived compounds specifically activate these pathways in dogs has not been established by controlled research.
Do mushroom extracts carry safety risks for dogs?
Published canine safety data for mushroom extracts are absent. The broader nutraceutical literature notes that drawbacks associated with the use or misuse of such substances have been documented (Nicotra et al., 2025; PMCID: PMC12568156). Dogs on immunosuppressive medications, those with immune-mediated diseases, or those with gastrointestinal conditions warrant veterinary consultation before introducing any immune-modulating supplement. Species-specific toxicity data for mushroom preparations have not been systematically collected in dogs.
Evidence-informed article
Pawsd Knowledge articles are educational and not a substitute for veterinary advice. These pages draw from selected open-access peer-reviewed veterinary research, with full-text sources linked below.
Selected references
Unknown. J Clin Med Res. 2025. DOI: 10.46889/jcmr.2025.6327. Uncontrolled case series combining owner-reported cognitive assessments with wearable activity monitoring for a mushroom-derived nutraceutical in dogs with cognitive decline.
Blanchard T, et al. GeroScience. 2025. PMCID: PMC12181554. Open-access systematic review of enriched diets and nutraceuticals for cognitive function in aging dogs and cats; reports inconsistent results across the literature.
Mihevc SP, Majdič G. Front Neurosci. 2019;13:604. PMCID: PMC6582309. Open-access narrative review of CCD pathology, prevalence, and management approaches including antioxidant-enriched diets.
Ambrosini YM, et al. Front Aging Neurosci. 2019;11:130. PMCID: PMC6591269. Open-access review documenting canine beta-amyloid accumulation and the dog as a model for neurodegenerative aging research.
Sechi S, et al. J Vet Med. 2015;2015:412501. PMCID: PMC4590864. Open-access pilot study (n=36) finding significant BDNF increases and oxidative stress reduction with an antioxidant-enriched diet in aged dogs.
Nicotra M, et al. Vet Sci (Basel). 2025;12(10):964. PMCID: PMC12568156. Open-access narrative review of nutraceutical properties including antioxidant, anti-inflammatory, and cognitive-enhancing effects in pets.
Cai X, et al. Animals (Basel). 2026;16(4):571. DOI: 10.3390/ani16040571. Open-access review identifying oxidative stress and mitochondrial dysfunction as key drivers of cognitive impairment in aging pets and documenting evidence gaps.
Related Reading
Dog-Appeasing Pheromone (DAP): Efficacy and Evidence Review
An evidence-based review of dog-appeasing pheromone (DAP) efficacy, vomeronasal processing mechanisms, and clinical limitations in canine behavioral therapy.
Dog Anxiety Medication: What a Vet May Discuss
A clinical overview of canine anxiety medication — when it's appropriate, what a medication trial involves, common owner concerns, and why it works alongside training rather than replacing it. All decisions belong to the veterinarian.
Ashwagandha for Dogs: Evidence, Mechanisms, and Limitations
Ashwagandha root extract (Withania somnifera) has been studied in geriatric dogs via two small RCTs. What the trials measured, what they found, and where the evidence falls short.
The First Week After Adopting a Dog: Physiological and Behavioral Adjustment
Shelter dogs arrive with elevated physiological stress markers that require time to down-regulate. This guide examines what the research shows about the adjustment arc in newly adopted dogs: the physiological baseline at adoption, the 3-3-3 framework for behavioral adjustment, how schedule predictability reduces arousal, the case for introducing alone time early, and what adopter expectation surveys document about the gap between expected and experienced outcomes.
© 2026 Pawsd LLC. All rights reserved. The selection, arrangement, and original commentary in this guide are the copyrighted work of Pawsd. While the underlying research is publicly available, the editorial analysis, evidence curation, and breed-specific guidance reflect original work. Reproduction or redistribution of this material without written permission is prohibited. For licensing inquiries, contact hello@pawsd.ai.